Gilead Sciences Makes Strategic $7.8 Billion Oncology Move

Gilead Sciences buys partner Arcellx for up to $7.8B, securing a promising multiple myeloma therapy to counter competitive pressures and declining drug sales.

In a decisive push to reshape its oncology portfolio, Gilead Sciences has announced an agreement to acquire its partner, Arcellx, for up to $7.8 billion. This acquisition is centered on securing a novel cell therapy that Gilead believes will position it for leadership in the competitive multiple myeloma market. The move represents a strategic counter to mounting competitive pressures and declining revenue from some of its established cancer treatments.

Financial Performance and Shareholder Returns

The transaction is underpinned by Gilead's solid financial footing. The company recently reported quarterly adjusted earnings per share of $1.86 on revenue of $7.93 billion. For the full 2026 fiscal year, management is targeting adjusted EPS in the range of $8.45 to $8.85. Demonstrating confidence in its financial stability, the board also approved a 3.8% increase in the quarterly dividend to $0.82 per share.

Despite a strong start to the year with shares up nearly 21%, the stock currently trades slightly below its 52-week high of €131.20. The closing price on Tuesday was €125.36.

• Tuesday's Close: €125.36
• Year-to-Date Performance: +20.79%
• 52-Week High: €131.20 (February 11, 2026)

Terms of the Arcellx Acquisition

Under the deal's terms, Gilead will pay $115 in cash for each Arcellx share, representing a 68% premium over the volume-weighted average price from the past 30 trading days. Arcellx shareholders are also eligible for an additional $5 per share via a non-tradable contingent value right (CVR). This payout is contingent upon the company's lead drug candidate, Anito-cel, achieving cumulative sales of at least $6 billion by the end of 2029.

Gilead, which already held an 11.5% stake in the biotech firm, will gain full control of the asset. The buyout also allows Gilead to eliminate potential future milestone payments totaling up to $3.9 billion that would have been due under the existing collaboration agreement.

A Forward-Looking Strategy in a Shifting Market

Industry observers see this acquisition as a timely strategic pivot. Gilead is confronting revenue softness in parts of its existing oncology business; for instance, sales of its established therapy Yescarta declined by 5.6% to $368 million in the fourth quarter of 2025. Anito-cel is intended to compete directly with rival blockbuster therapies in the multiple myeloma space.

Clinical data provides a foundation for optimism. In a Phase 2 study, the therapy demonstrated a 96% overall response rate in patients with multiple myeloma. Company leadership projects that, assuming a successful commercial launch, the transaction will begin contributing positively to earnings per share starting in 2028.

The next critical milestone is scheduled for December 23, 2026, which is the deadline for the U.S. Food and Drug Administration (FDA) to decide on the approval of Anito-cel.